RIPK3 and melanoma: We co-cultured CV-stimulated depigmented melanoma cells with selected kinases inhibitors: necrostatin-1 (Nec-1), GSK’872 and necrosufonamide (NSA), which specifically target RIPK1, RIPK3, and MLKL activity, respectively [42,43,44].